Top

Published in:

01-05-2009 | Original Article

Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months

Authors: Elise L. Lev, Lucille Sanzero Eller, Glen Gejerman, John Kolassa, Joan Colella, Janine Pezzino, Patricia Lane, Ravi Munver, Michael Esposito, John Sheuch, Vincent Lanteri, Ihor Sawczuk

Published in: Supportive Care in Cancer | Issue 5/2009

Abstract

Goals of work

Treatments for early-stage prostate cancer (PCa) are highly effective; therefore, research studies that explore quality of life (QOL) issues associated with different treatments are important. The purposes of this study were to (a) examine differences among treatment groups of men treated with either radiation therapies or radical prostatectomy for PCa and (b) examine quality of life outcomes over time.

Patients and methods

We report outcomes 6 and 12 months after 159 men began treatment for PCa with either one of two types of radiation treatment (intensity-modulated radiation therapy plus high dose rate or intensity-modulated radiation therapy plus seed implantation) or radical prostatectomy.

Main results

Significant differences among groups are described. Significant predictors of QOL at 6 months included urinary, bowel, and sexual symptoms, anxiety, depression, problem-focused coping, and physiological self-efficacy. Significant predictors of QOL at 12 months were urinary and bowel symptoms, stress, depression, problem-focused coping, and physiological self-efficacy. Demographic variables, race, and living status were significant predictors of quality of life at 12 months.

Conclusions

Physiological symptoms and psychological symptoms were both significant predictors of QOL. The psychological factors that predicted quality of life in this study have potential for intervention and point to the next stage of the research.

Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DR et al (2006) Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol 20(10):723–731 doi:10.1089/end.2006.20.723 PubMedCrossRef

Bandura A (1997) Self-efficacy. The exercise of control. Freeman, New York

Ben-Tovim DI, Dougherty ML, Stapleton AM, Pinnock CB (2006) Coping with prostate cancer: a quantitative analysis using a new instrument, the centre for clinical excellence in urological research coping with cancer instrument. Urology 59(3):383–388 doi:10.1016/S0090-4295(01)01540-0 CrossRef

Campbell LC, Keefe FJ, McKee DC, Edwards CL, Herman SH, Johnson LE et al (2004) Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life. J Pain Symptom Manage 28(5):433–444 doi:10.1016/j.jpainsymman.2004.02.020 PubMedCrossRef

Cella D (1995) Measuring quality of life in palliative care. Semin Oncol 22:73–81PubMed

Cella D (1997) Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement System. Version 4, Evanston, Il: Center on Outcomes, Research and Education (CORE). Evanston Northwestern Healthcare and Northwestern University, Evanston, IL

Chen RC, Clark JA, Manola J, Talcott JA (2008) Treatment ‘mismatch’ in early prostate cancer: do treatment choices take patient quality of life into account. Cancer 112(1):61–68 doi:10.1002/cncr.23138 PubMedCrossRef

Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385–396 doi:10.2307/2136404 PubMedCrossRef

Derogatis LR (1994) SCLR-90-R Symptom checklist-90-R administration, scoring and procedures manual, 3rd edn. National Computer Systems, Inc., Minneapolis, MN

10.

Eller LS, Lev EL, Gejerman G, Colella J, Esposito M, Lanteri V et al (2006) Prospective study of quality of life of patients receiving treatment for prostate cancer. Nurs Res 55(2):S28–S36PubMed

11.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, European Association of Urology et al (2008) EAU guidelines on prostate cancer. Aur Urol 53(1):68–80 doi:10.1016/j.eururo.2007.09.002 CrossRef

12.

Kurtz ME, Kurtz JC, Stommel M, Given CW, Given B (2001) Physical functioning and depression among older persons with cancer. Cancer Pract 9(1):11–18 doi:10.1046/j.1523-5394.2001.91004.x PubMedCrossRef

13.

Lazarus RS, Folkman S (1984) Stress, appraisal, and coping. Springer, New York

14.

Lev EL, Eller LS, Kolassa J, Gejerman G, Colella J, Lane P et al (2006) Exploratory factor analysis: strategies used by patients to promote health. World J Urol 25:87–93 doi:10.1007/s00345-006-0126-7 CrossRef

15.

Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R et al (2003) Prostate cancer patients’ support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology 12:769–783 doi:10.1002/pon.702 PubMedCrossRef

16.

Loscalzo MJ (2002) The Pirl/Mello article reviewed. Oncology 16(1):1458–1467

17.

Movsas B, Scott C, Watkins-Bruner D (2006) Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys 65(3):830–835 doi:10.1016/j.ijrobp.2006.01.004 PubMed

18.

Penedo FJ, Molton I, Dahn JR, Shen BJ, Kinsinger D, Traeger L et al (2006) A randomized clinical trial of group-based cognitive–behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med 31(3):261–270 doi:10.1207/s15324796abm3103_8 PubMedCrossRef

19.

Phan TP, Syed AM, PUthawala A, Sharma A, Khan F (2007) High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 117(1):123–127, discussion 127 doi:10.1016/j.juro.2006.08.109 CrossRef

20.

Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401 doi:10.1177/014662167700100306 CrossRef

21.

Sharpley CF, Christie DRH (2007) An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer. Psychooncology 16:660–667 doi:10.1002/pon.1118 PubMedCrossRef

22.

Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, TAngen CM, AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(6):2106–2131 doi:10.1016/j.juro.2007.03.003 PubMedCrossRef

23.

Zakowski SG, Harris C, Krueger N, Laubmeier KK, Garrett S, Flanigan R et al (2003) Social barriers to emotional expression and their relations to distress in male and female cancer patients. Br J Health Psychol 8(Pt3):271–286 doi:10.1348/135910703322370851 PubMedCrossRef

Title: Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months
Authors: Elise L. Lev
Lucille Sanzero Eller
Glen Gejerman
John Kolassa
Joan Colella
Janine Pezzino
Patricia Lane
Ravi Munver
Michael Esposito
John Sheuch
Vincent Lanteri
Ihor Sawczuk
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0493-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Goals of work

Patients and methods

Main results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Febrile neutropenia and periodontitis: lessons from a case periodontal treatment in the intervals between chemotherapy cycles for leukemia reduced febrile neutropenia

Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting

The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience

Prognostic implications of emergency admission and delays in patients with breast cancer

Hyperparathyroidism secondary to zoledronic acid infusion: case report

Patterns of fatigue related to advanced disease and radiotherapy in patients with cancer—a comparative cross-sectional study of fatigue intensity and characteristics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer